MAPT and Alzheimer disease: The exogenous introduction of soluble tau aggregates and oligomers, derived from the brains of Alzheimer’s disease patients, into animal models induced cognitive impairment in mice, a phenomenon potentially explained by in vitro evidence of impaired hippocampal synaptic plasticity [235,236].